drugset / Trial / NCT07164170
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.
Timeline
- Start
- 2025-09-22
- Primary completion
- 2028-12-30
- Completion
- 2029-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABSK043 | Small molecule | 150 mg | — |
| Subject | Glecirasib | Small molecule | 200 mg | — |